Xenetic Biosciences, Inc. (NASDAQ: XBIO)
Quick summary - what's happening inside
* The company remains pre‑clinical, advancing its DNase oncology program and funding operations largely from legacy royalties and cash on hand.
* Management says existing resources should fund operations for at least...